Venture philanthropy fund appoints Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD; and Steven Pipe, MD
New York, NY – Pathway to Cures (P2C), a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, has named Katherine High, MD; Haiyan Jiang, PhD; Glenn Pierce, MD, PhD and Steven Pipe, MD, to its Scientific Advisory Group. Leonard Valentino, MD, P2C’s Chief Executive Officer and NHF President and CEO, also serves on the Scientific Advisory Group.
“We are delighted to have such high-caliber advisors to support best practices in early-stage investing, which initially will focus on opportunities in non-viral-mediated gene therapy, gene editing platforms, and next-generation cures and therapies,” said Michael Recht, MD, PhD, MBA. Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Hemophilia Foundation (NHF) and chairs the Pathway to Cures Scientific Advisory Group.
P2C brings investment dollars, knowledge, and scientific and community relationships together to facilitate development of new products to address the unmet needs of the bleeding and blood disorders community. P2C’s Scientific Advisory Board makes recommendations to the P2C Investment Committee regarding promising opportunities.
Inheritable blood and bleeding disorders include rare and ultra-rare blood disorders, hemophilia A and B, von Willebrand disease, sickle cell disease, anemia, clotting disorders, and other hematological disorders, affecting more than 20 million people worldwide.
For more information, visit www.pathwaytocures.org or contact Renee Peck at firstname.lastname@example.org.
About Pathway to Cures
Pathway to Cures (P2C) is a venture philanthropy fund created to accelerate development of cures across all inheritable blood disorders. In collaboration with other organizations, P2C invests in innovative therapies and technologies, leveraging the deep resources and scientific community relationships of its parent organization, the National Hemophilia Foundation (NHF). By reinvesting proceeds from investments back into the Fund, P2C will amplify investment impact, support promising companies and build portfolio of investments that further the P2C mission.
About National Hemophilia Foundation
The National Hemophilia Foundation is dedicated to finding better treatments and cures for inheritable blood disorders and to preventing complications through education, advocacy, and research. For more information, visit hemophilia.org.